MaxCyte (NasdaqGS:MXCT) Q4 2025 Earnings call March 24, 2026 04:30 PM ET Company ParticipantsDouglas Swirsky - CFOErik Abdo - Director of Investor RelationsMaher Masoud - President and CEOSean Menarguez - Senior Director of Business DevelopmentVidyun Bais - VP in Equity ResearchConference Call ParticipantsChad Wiatrowski - AnalystDan Arias - Managing Director & Senior Equity Research AnalystJacob Johnson - AnalystMatt Etoch - Research AnalystMatt Hewitt - Senior Research AnalystOperatorPlease note, this con ...

MaxCyte (NasdaqGS:MXCT) Q4 2025 Earnings call March 24, 2026 04:30 PM ET Company ParticipantsDouglas Swirsky - CFOErik Abdo - Director of Investor RelationsMaher Masoud - President and CEOSean Menarguez - Senior Director of Business DevelopmentVidyun Bais - VP in Equity ResearchConference Call ParticipantsChad Wiatrowski - AnalystDan Arias - Managing Director & Senior Equity Research AnalystJacob Johnson - AnalystMatt Etoch - Research AnalystMatt Hewitt - Senior Research AnalystOperatorPlease note, this con ...

MaxCyte (NasdaqGS:MXCT) Q4 2025 Earnings call March 24, 2026 04:30 PM ET Speaker8Please note, this conference is being recorded. Now we'll turn the call over to Erik Abdo with Investor Relations. Please proceed.Speaker3Good afternoon, everyone. Thank you for participating in today's conference call. Joining me on the call from MaxCyte, we have Maher Masoud, President and Chief Executive Officer, Douglas Swirsky, Chief Financial Officer, and Sean Menarguez, Senior Director of Business Development. Earlier to ...

Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement Full year 2025 revenue of $33.0 million, at the top of the range of previous preliminary announcement Total cash, cash equivalents and investments were $155.6 million as of December 31, 2025. Expects to end 2026 with at least $136 million in total cash, cash equivalents and investments Expects 2026 revenue of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) ...

Core Insights - MaxCyte, Inc. has appointed Parmeet Ahuja as Chief Financial Officer effective March 30, 2026, succeeding Douglas Swirsky [1] - Ahuja brings over 20 years of finance leadership experience, particularly in the life sciences sector, having previously served as Vice President of Investor Relations at Agilent Technologies [2] - Ahuja expressed enthusiasm about joining MaxCyte, highlighting the transformative potential of the company's electroporation platform for the Cell and Gene Therapy industry [3] Company Overview - MaxCyte is a leading cell-engineering company focused on advancing the discovery, development, and commercialization of next-generation cell therapies [3] - The company utilizes its Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services to enable precise and scalable cell engineering [3] - MaxCyte has over 25 years of experience in cell engineering, contributing to the future of medicine [3]

ROCKVILLE, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the launch of ExPERT DTx™, a new high throughput transfection platform for research and drug discovery applications. This modular, 96-well electroporation system enables labs to transfect primary cells and cell lines with minimal ce ...

Core Viewpoint - MaxCyte, Inc. is set to release its financial results for Q4 and full year 2025 on March 24, 2026, after U.S. market close, with a conference call scheduled for 4:30 p.m. Eastern Time to discuss these results [1]. Group 1: Financial Results Announcement - The financial results for the fourth quarter and full year 2025 will be announced after the U.S. market closes on March 24, 2026 [1]. - A conference call will be held at 4:30 p.m. Eastern Time to discuss the financial results [1]. Group 2: Conference Call Details - Investors interested in the conference call must register online, with a recommendation to register at least a day in advance [2]. - A live and archived webcast of the conference call will be available on the MaxCyte website [2]. Group 3: Company Overview - MaxCyte is a leading cell-engineering company focused on advancing the discovery, development, and commercialization of next-generation cell therapies [3]. - The company utilizes Flow Electroporation technology and SeQure DX gene editing risk assessment services to enable precise and scalable cell engineering [3]. - With over 25 years of experience, MaxCyte aims to shape the future of medicine by empowering researchers globally to develop safe and effective treatments [3].

Financial Results - MaxCyte, Inc. announced preliminary unaudited financial results for Q4 and fiscal year ended December 31, 2025[4] - The press release detailing financial results was issued on January 12, 2026[4] Company Classification - The company is classified as an emerging growth company under the Securities Act of 1933[3]

Core Insights - MaxCyte, Inc. provided a preliminary update on its financial results for Q4 and the full year 2025, indicating a challenging yet productive year with core revenue in line with guidance [1][3] - The company reported total cash, cash equivalents, and investments of approximately $155.6 million as of December 31, 2025 [2] - Core revenue for Q4 is expected to be between $6.6 million and $6.7 million, while full-year core revenue is projected to be between $29.5 million and $29.6 million [5] - Strategic Platform License (SPL) program-related revenue for Q4 is expected to be between $0.4 million and $0.6 million, with full-year SPL revenue anticipated to be between $3.3 million and $3.5 million [5] Company Strategy and Outlook - The company aims to improve its cost structure and drive efficient growth towards profitability, entering 2026 with reduced annual burn and a leaner organization [3] - MaxCyte is optimistic about the opportunities presented by its SPLs and the expansion of its SeQure services, expecting a return to revenue growth in the second half of 2026 [3] - The company plans to launch new offerings early in 2026, indicating a focus on innovation and market expansion [3] Technology and Services - MaxCyte specializes in cell engineering, providing technologies that facilitate the discovery, development, and commercialization of next-generation cell therapies [4] - The company’s Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services are designed to enable precise and scalable cell engineering [4] - With over 25 years of experience, MaxCyte continues to advance cell engineering, contributing to the future of medicine [4]

MaxCyte FY Conference Summary Company Overview - **Company**: MaxCyte (NasdaqGS:MXCT) - **Industry**: Cell and Gene Therapy Key Points and Arguments Strategic Focus and Changes - MaxCyte has undergone significant changes, including a CFO transition, acquisition of SecureDx, and operational restructuring to enhance focus on scientific, engineering, and commercial teams [3][4][6] - The company has grown from approximately 50 employees pre-COVID to around 90 employees, reflecting its expansion in the cell and gene therapy space [4][6] Acquisition of SecureDx - The acquisition of SecureDx is seen as a strategic move to enhance MaxCyte's capabilities in early-stage customer engagement and safety profiling in gene therapy [4][5][12] - SecureDx's offerings align with FDA's focus on safety assessments, particularly in gene editing therapies [14][15][43] Market Dynamics and Demand - The cell and gene therapy market has faced rationalization, with developers reducing the number of programs they are pursuing, impacting the number of licenses used in clinics [17][18] - Despite headwinds, MaxCyte is experiencing larger placements of instruments and continues to sign strategic platform licenses (SPLs), with four signed in the current year [19][20] Product Offerings and Differentiation - MaxCyte specializes in non-viral cell engineering, providing scalable solutions for ex vivo cell therapy, including the introduction of gene editing tools like CRISPR [9][10][11] - The company is expanding its offerings with a new product set to launch early next year, aimed at early-stage research and development [47][48] Financial Performance and Projections - MaxCyte anticipates a cash burn of $10 million to $15 million for the next year, significantly reduced from previous years, with a focus on achieving profitability [54][55] - The company expects to return to historical gross margins of 84%-85% as revenue grows, despite recent fluctuations due to changes in product mix [49][51][53] Future Outlook - MaxCyte is optimistic about growth in the second half of 2026, driven by new product launches, expansion in Asia, and a focus on core business development [60][61] - The company believes in the long-term potential of cell and gene therapies to address diseases in ways that traditional therapies cannot [62] Regulatory Environment - The FDA's increasing scrutiny on safety in gene editing therapies is creating opportunities for MaxCyte to position itself as a leader in non-viral solutions [22][24][25] Customer Engagement - MaxCyte is seeing increased interest from customers in non-viral therapies due to safety concerns associated with viral delivery methods [22][24] - The company aims to engage with customers earlier in the development process to help mitigate risks associated with off-target effects [25][26] Additional Important Insights - The company has developed over 1,000 protocols for various cell types and gene editing tools, positioning itself well for the growing allogeneic therapy market [30][29] - MaxCyte's focus on scientific engagement and customer relationships is expected to drive future growth and innovation in the cell and gene therapy space [41][42] This summary encapsulates the key insights from the MaxCyte FY Conference, highlighting the company's strategic direction, market dynamics, product offerings, and future outlook in the cell and gene therapy industry.